Dynavax Technologies 株価情報 (NASDAQ: DVAX)

Dynavax Technologies (NASDAQ:DVAX) 株価情報

Dynavax Technologies

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies Corp

News

Health Care

Buybacks

General

DVAX

Dynavax Intends To Repurchase Approximately $8M

<ul>
<li>Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure</li>
<li>$225 million of convertible notes due in 2030 issued, including an exchange for the retirement of ~$185 million of existing convertible notes due in 2026 and ~$40 million of new money</li>
</ul>

Financing

Dynavax Has Entered Into Privately Negotiated Exchange And Subscription Agreements To Issue $225M  2.0% Convertible Senior Notes Due 2030

During the last three months, 4 analysts shared their evaluations of Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.75, a high estimate of $33.00, and a low estimate of $12.00. Surpassing the previous average price target of $26.00, the current average has increased by 2.88%.
<img src="https://www.benzinga.com/files/images/story/2025/1740168014_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Dynavax Technologies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Butler</td>
<td>Citizens Capital Markets</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$33.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$31.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dynavax Technologies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dynavax Technologies compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Dynavax Technologies's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Dynavax Technologies's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DVAX/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dynavax Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Dynavax Technologies</h2>
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
<h3>Unraveling the Financial Story of Dynavax Technologies</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Dynavax Technologies's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 15.99%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Dynavax Technologies's net margin excels beyond industry benchmarks, reaching 21.82%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Dynavax Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of 2.66%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Dynavax Technologies's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.69%, the company showcases efficient use of assets and strong financial health.
Debt Management: Dynavax Technologies's debt-to-equity ratio stands notably higher than the industry average, reaching 0.37. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Dynavax Technologies Stock: Analyst Perspectives (4 Ratings)

Citizens Capital Markets analyst Jason Butler maintains Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Market Outperform and raises the price target from $29 to $33.

Price Target

Citizens Capital Markets Maintains Market Outperform on Dynavax Technologies, Raises Price Target to $33

HC Wainwright &amp; Co. analyst Edward White reiterates Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Buy and maintains $31 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $31 Price Target

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.04 by 25 percent. The company reported quarterly sales of $72.03 million which missed the analyst consensus estimate of $72.70 million by 0.92 percent. This is a 29.56 percent increase over sales of $55.60 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Dynavax Technologies Q4 GAAP EPS $0.05 Beats $0.04 Estimate, Sales $72.03M Miss $72.70M Estimate

ACCO

AKAM

ALIT

ALRM

ARDX

ATHM

AXTI

BABA

BAND

BBDC

BBIO

BIGC

BILI

BIRK

BJRI

BKNG

BLDR

CARG

CCRD

CDRO

CELH

CENX

CERS

CGAU

COKE

COLD

CPRT

CRAI

CSTM

DAVA

DBRG

DGICA

DGICB

DINO

EPAM

ESAB

EXPI

FIVN

FRPT

FYBR

GDYN

GKOS

GLOB

GLPI

GMED

GRAL

INDI

INDV

INOD

INSM

IRTC

ITGR

Earnings Scheduled For February 20, 2025

Dynavax Confirms That Deep Track Capital Submitted Letter To Nominate Four Candidates To Stand For Election To Board; Says Meaningful Board Change Already Underway

Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reflecting updated views and recent competitive <a target="_blank" href="https://www.benzinga.com/quote/DVAX" rel="noreferrer noopener">dynamics for vaccines</a>.
Goldman Sachs analyst Paul Choi has downgraded Dynavax to Sell from Neutral and cut the <a target="_blank" href="https://www.benzinga.com/quote/DVAX/analyst-ratings" rel="noreferrer noopener">price target from $15 to $12</a>. He notes growing competition in the shingles vaccine market, which could reduce the potential value of the Z-1018 program and add uncertainty to its long-term revenue.
Potential convenience improvements come from GSK Plc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Shingrix with the company's pre-filled syringes, which have been accepted for review by <a target="_blank" href="https://www.benzinga.com/25/02/43492835/gsk-launches-share-buyback-of-around-25-billion-after-better-than-expected-q4-earnings-raises-long-term-annual-sales-forecast-to-over-50-billion" rel="noreferrer noopener">both the FDA and EMA</a> (U.S. decision expected by 20 June).
Dynavax is conducting a Phase 1/2 trial to evaluate the safety, tolerability, and immunogenicity of Z-1018 compared to GSK's Shingrix in 441 healthy adults aged 50 to 69.
Choi also points to uncertain demand for repeat hepatitis B vaccinations in the 2030s, which may impact Heplisav-B's outlook beyond its peak sales. Despite its market share gains, questions remain about the FDA and ACIP's regulatory stance on vaccines in the U.S.
Last month,&nbsp;Dynavax announced preliminary HEPLISAV-B net product revenue of&nbsp;$268 million&nbsp;for 2024, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42945098/dynavax-announces-preliminary-unaudited-fourth-quarter-and-full-year-2024-financial-highlights" rel="noreferrer noopener">up 26% year-over-year</a>.
HEPLISAV-B net product revenue reached&nbsp;$71 million&nbsp;for the fourth quarter of 2024, up 39%.
In May 2024, the FDA issued a Complete Response Letter stating that the application did not provide sufficient data to fully evaluate the effectiveness or safety of a four-dose <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38818397/fda-declines-to-approve-expanded-use-of-dynavaxs-hepatitis-b-vaccine-in-hemodialysis-patients" rel="noreferrer noopener">regimen of HEPLISAV-B</a>.&nbsp;
Dynavax is expected to report fourth-quarter earnings <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43548293/dynavax-to-report-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-" rel="noreferrer noopener">on 20 February</a>.
As per data from Benzinga Pro, analysts estimate Q4 adjusted EPS of $0.04, with sales of $72.92 million.
Analysts forecast 2024 sales of $278.13 million and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">adjusted EPS of $0.12</a>.
Price Action: DVAX stock is down 4.13% at $12.66 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43629227/nano-cap-lipella-pharmaceuticals-stock-jumps-on-positive-trial-data-in-patients-with-sore-mouth-membranes" target="_blank" rel="noreferrer noopener">Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes</a></li>
</ul>

Analyst Color

Biotech

Downgrades

Movers

Trading Ideas

Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty

WIIM

Dynavax shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Oppenheimer analyst Tyler Batory downgraded the rating for Playa Hotels &amp; Resorts N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLYA#NASDAQ">PLYA</a>) from Outperform to Perform. Playa Hotels shares closed at $13.24 on Monday. <a href="https://www.benzinga.com/quote/PLYA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Ameet Thakkar downgraded Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) from Outperform to Market Perform and lowered the price target from $22 to $10. Fluence Energy shares closed at $13.07 on Monday. <a href="https://www.benzinga.com/quote/FLNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Paul Choi downgraded the rating for Dynavax Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) from Neutral to Sell and slashed the price target from $15 to $12. Dynavax shares closed at $13.20 on Monday. <a href="https://www.benzinga.com/quote/DVAX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Christopher Raymond downgraded Q32 Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) from Overweight to Neutral and cut the price target from $20 to $4. Q32 Bio shares closed at $3.18 on Monday. <a href="https://www.benzinga.com/quote/QTTB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Matt Summerville downgraded the rating for Columbus McKinnon Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCO#NASDAQ">CMCO</a>) from Buy to Neutral and announced a $35 price target. Columbus McKinnon shares closed at $35.48 on Monday. <a href="https://www.benzinga.com/quote/CMCO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CMCO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91-1024x593.png" alt="" class="wp-image-776431" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91.png 1108w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43592071/top-3-tech-stocks-that-may-jump-this-month">Top 3 Tech Stocks That May Jump This Month</a></li>
</ul>
Photo: Shutterstock

Pre-Market Outlook

Markets

CMCO

FLNC

PLYA

QTTB

This Columbus McKinnon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Goldman Sachs analyst Paul Choi downgrades Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) from Neutral to Sell and lowers the price target from $15 to $12.

Goldman Sachs Downgrades Dynavax Technologies to Sell, Lowers Price Target to $12

HC Wainwright &amp; Co. analyst Edward White maintains Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Buy and raises the price target from $29 to $31.

HC Wainwright & Co. Maintains Buy on Dynavax Technologies, Raises Price Target to $31

Guidance

Dynavax Prelim. 2024 HEPLISAV-B Net Product Revenue Grew 26% YoY To $268M

Dynavax Announces $100M Accelerated Share Repurchase Program Under Agreement With Goldman Sachs

Dynavax Technologies shares are trading higher after the company reported better-than-expected Q3 EPS results and launched a $200 million share buyback program. HC Wainwright & Co. reiterated a Buy rating on the stock.

HC Wainwright &amp; Co. analyst Edward White reiterates Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Buy and maintains $29 price target.

HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $29 Price Target

Dynavax Launches $200M Share Buyback Program With Board Approval; Repurchases Expected To Be Completed Within One Year

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.11 by 9.09 percent. The company reported quarterly sales of $80.630 million which missed the analyst consensus estimate of $84.166 million by 4.20 percent. This is a 15.99 percent increase over sales of $69.514 million the same period last year.

Dynavax Technologies Q3 2024 GAAP EPS $0.12 Beats $0.11 Estimate, Sales $80.630M Miss $84.166M Estimate

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) will release its quarterly earnings report on Thursday, 2024-11-07. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Dynavax Technologies to report an earnings per share (EPS) of $0.11.
The announcement from Dynavax Technologies is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.02, leading to a 6.97% increase in the share price the following trading session.
Here's a look at Dynavax Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.06</td>
<td>-0.02</td>
<td>-0.01</td>
<td>-0.01</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.08</td>
<td>-0.07</td>
<td>0</td>
<td>0.10</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.000000000000001%</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730919682_0.png" alt="eps graph" />
<h3>Performance of Dynavax Technologies Shares</h3>
Shares of Dynavax Technologies were trading at $12.01 as of November 05. Over the last 52-week period, shares are down 6.38%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on Dynavax Technologies</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Dynavax Technologies.
The consensus rating for Dynavax Technologies is Buy, based on 2 analyst ratings. With an average one-year price target of $22.0, there's a potential 83.18% upside.
<h3>Comparing Ratings with Competitors</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Myriad Genetics and Kiniksa Pharmaceuticals, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Neutral trajectory for Myriad Genetics, with an average 1-year price target of $32.75, indicating a potential 172.69% upside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Kiniksa Pharmaceuticals, with an average 1-year price target of $38.33, indicating a potential 219.15% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Myriad Genetics and Kiniksa Pharmaceuticals, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dynavax Technologies</td>
<td>Buy</td>
<td>22.48%</td>
<td>$61.81M</td>
<td>1.81%</td>
</tr>
<tr>
<td>Myriad Genetics</td>
<td>Neutral</td>
<td>15.26%</td>
<td>$147.10M</td>
<td>-4.89%</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals</td>
<td>Outperform</td>
<td>67.37%</td>
<td>$62.80M</td>
<td>-2.91%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Dynavax Technologies ranks highest in Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Dynavax Technologies is at the bottom compared to its peers.
<h3>Delving into Dynavax Technologies's Background</h3>
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
<h3>Breaking Down Dynavax Technologies's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Dynavax Technologies showcased positive performance, achieving a revenue growth rate of 22.48% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Dynavax Technologies's net margin is impressive, surpassing industry averages. With a net margin of 15.43%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Dynavax Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of 1.81%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Dynavax Technologies's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.14%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.39, Dynavax Technologies faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/DVAX/earnings">To track all earnings releases for Dynavax Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Dynavax Technologies's Upcoming Earnings

Press Releases

Dynavax to Present at the 7th Annual Evercore HealthCONx Conference

Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights

Dynavax Advances Board Refreshment Program

Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025

Penny Stocks

Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy

Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance

Dynavax to Participate in Upcoming Investor Conferences

Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase

Comments

Dynavax Technologies

ニュース

パートナーシップ

ベンジンガ・グローバル